CDM 050
Alternative Names: CDM-050Latest Information Update: 28 Feb 2020
Price :
$50 *
At a glance
- Originator Kao Corporation
- Class Skin disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Skin disorders
Most Recent Events
- 28 Feb 2020 No recent reports of development identified for phase-I development in Skin-disorders(In volunteers) in Japan (Topical)
- 04 Apr 2017 Kao Corporation completes a phase I trial in Healthy volunteers in Japan (UMIN000025668)
- 26 Jan 2017 Phase-I clinical trials in Skin disorders in Japan (Topical) (UMIN000025668)